source
- J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotechThe in vivo CAR-T space is getting more competitive as one of the biggest cell therapy players expands its role. Johnson & Johnson is paying $785 million upfront to work with Flagship Pioneering's…Endpoints · 35m ago↗ source
- FDA advisory panel rejects Capricor’s Duchenne cardiomyopathy cell therapyA FDA advisory committee voted against Capricor’s cell therapy for Duchenne muscular dystrophy cardiomyopathy, with nine members opposing and three supporting the product. The therapy, called dera…